Download PDF
Thromb Haemost 1997; 78(01): 693-698
DOI: 10.1055/s-0038-1657614
Prevention and treatment of deep vein thrombosis
Schattauer GmbH Stuttgart

Optimal Duration of Oral Anticoagulant Therapy in Venous Thromboembolism

Sam Schulman
Unit of Blood Coagulation, Division of Hematology and Infectious diseases, Department of Medicine, Karolinska Hospital, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Bynum LJ, Wilson JE. Low-dose heparin therapy in the longterm management of venous thromboembolism. Am J Med 1979; 67: 553-556
    CrossrefPubMedGoogle Scholar
  • 2 Vitoux J-F, Fiessinger J-N, Roncato M, Pernes J-M, Brenot P, Aiach M. Long-term treatment of acute deep venous thrombosis with low-molecular-weight heparin derivative. JAMA 1988; 259: 1180-1181
    CrossrefPubMedGoogle Scholar
  • 3 Lehman J. Hypoprothrombinaemia produced by methylene-bis-(hydroxycoumarin), its use in thrombosis. Lancet 1942; 01: 318
    PubMedGoogle Scholar
  • 4 Allen EV, Barker NW, Waugh JM. A preparation from spoiled sweet clover (3,3'-methylene-bis-(4-hydroxycoumarin)) which prolongs coagulation and prothrombin time of the blood: a clinical study. JAMA 1942; 120: 1009-1015
    CrossrefPubMedGoogle Scholar
  • 5 O’Sullivan EF. Duration of anticoagulant therapy in venous thromboembolism. Med J Aust 1972; 02: 1104-1107
    PubMedGoogle Scholar
  • 6 Holmgren K, Andersson G, Fagrell B, Johnsson H, Ljungberg B, Nilsson E, Wilhelmsson S, Zetterquist S. 1 month versus 6 months therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218: 279-284
    PubMedGoogle Scholar
  • 7 Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis-a randomized study. Acta Med Scand 1985; 217: 547-552
    PubMedGoogle Scholar
  • 8 Fennerty AG, Dolben J, Thomas P, Backhouse G, Bentley DP, Campbell IA, Routledge PA. A comparison of 3 and 6 weeks’ anticoagulation in the treatment of venous thromboembolism. Clin lab Haemat 1987; 09: 17-21
    CrossrefPubMedGoogle Scholar
  • 9 Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-876
    CrossrefPubMedGoogle Scholar
  • 10 Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jӧnsson K-Å, Hjorth M, Linder O, Boberg J. and The Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-1665
    CrossrefPubMedGoogle Scholar
  • 11 Schulman S, Granqvist S, Holmstrӧ M, Carlsson A, Lindmarker P, Nicol P, Eklund S-G, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E. and The Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997. 336. in press
    Google Scholar
  • 12 Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P, Piovella F. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Petitti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulant therapy and the probability of recurrent thromboembolism and haemorrhage. Am J Med 1986; 81: 255-259
    CrossrefPubMedGoogle Scholar
  • 14 Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 01-07
    PubMedGoogle Scholar
  • 15 Sarasin FP. Bounameaux. Duration of oral anticoagulant therapy after proximal deep vein thrombosis: a decision analysis. Thromb Haemostas 1994; 71: 286-291
    PubMedGoogle Scholar
  • 16 Bounameaux H, de MoerlooseP, Sarasin FP. Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs. Blood Coag Fibrinol 1996; 07: 507-514
    CrossrefPubMedGoogle Scholar
  • 17 Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The longterm clinical cause of acute deep venous thrombosis. Ann Int Med 1996; 125: 01-07
    CrossrefPubMedGoogle Scholar
  • 18 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited Thrombophilia: Part 2. Thromb Haemost 1996 76: 824-834
    PubMedGoogle Scholar
  • 19 Finazzi G, Barbui T. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin HI, protein C and protein S. Thromb Haemost 1994; 71: 15-18
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
    CrossrefPubMedGoogle Scholar
  • 21 Zӧller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
    CrossrefPubMedGoogle Scholar
  • 22 Rintelen C, Pabinger I, Knӧbl P, Lechner K, Mannhalter Ch. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75: 229-232
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035
    PubMedGoogle Scholar
  • 24 Zӧller C, Berntsdotter A, Garcia deFrutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523
    PubMedGoogle Scholar
  • 25 van BovenH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA. Fac tor V Leiden (FV R506Q) in families with antithrombin deficiency. Thromb Haemost. 1996. in press
    Google Scholar
  • 26 Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens Ch, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002
    CrossrefPubMedGoogle Scholar
  • 27 Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691
    PubMedGoogle Scholar
  • 28 Korninger C, Lechner K, Niessner H, Goessinger H, Kundi M. Impaired fibrinolytic capacity predisposes for recurrence of thrombosis. Thromb Haemost 1984; 52: 127-130
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, Goldhaber SZ, Hennekens CH. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992; 85: 1822-1827
    CrossrefPubMedGoogle Scholar
  • 30 Schulman S, Wiman B. and the Duration of Anticoagulation (DURAC) Trial Study Group. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996; 75: 607-611
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Elias A, Bonfils S, Daoud-Elias M, Gauthier B, Sié P, Boccalon H, Boneu B. Influence of long-term oral anticoagulants upon prothrombin fragment 1+2 thrombin-antithrombin III complex and D-dimer levels in patients affected by proximal deep vein thrombosis. Thromb Haemost 1993; 69: 302-305
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Andrew M, Marzinotto V, Brooker LA, Adams M, Ginsberg J, Freedom R, Williams W. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost 1994; 71: 265-269
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 David M, Manco-Johnson M, Andrew M. Diagnosis and treatment of venous thromboembolism in children and adolescents. Thromb Haemost 1995; 74: 791-792
    Article in Thieme ConnectPubMedGoogle Scholar